Clinical Trial Update: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing B cell-tailored ocrelizumab to standard ocrelizumab in relapsing-remitting multiple sclerosis; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: UNKNOWN